Time-dependent contraction of the SARS-CoV-2-specific T-cell responses in convalescent individuals.
J Allergy Clin Immunol Glob
; 1(3): 112-121, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-36203479
Background: Adaptive immunity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is decisive for disease control. Delayed activation of T cells is associated with a worse outcome in coronavirus disease 2019 (COVID-19). Although convalescent individuals exhibit solid T-cell immunity, to date, long-term immunity to SARS-CoV-2 is still under investigation. Objectives: We aimed to characterize the specific T-cell response on the basis of the in vitro recall of IFN-γ-producing cells to in silico-predicted peptides in samples from SARS-CoV-2 convalescent individuals. Methods: The sequence of the SARS-CoV-2 genome was screened, leading to the identification of specific and promiscuous peptides predicted to be recognized by CD4+ and CD8+ T cells. Next, we performed an in vitro recall of specific T cells from PBMC samples from the participants. The results were analyzed according to clinical features of the cohort and HLA diversity. Results: Our results indicated heterogeneous T-cell responsiveness among the participants. Compared with patients who exhibited mild symptoms, hospitalized patients had a significantly higher magnitude of response. In addition, male and older patients showed a lower number of IFN-γ-producing cells. Analysis of samples collected after 180 days revealed a reduction in the number of specific circulating IFN-γ-producing T cells, suggesting decreased immunity against viral peptides. Conclusion: Our data are evidence that in silico-predicted peptides are highly recognized by T cells from convalescent individuals, suggesting a possible application for vaccine design. However, the number of specific T cells decreases 180 days after infection, which might be associated with reduced protection against reinfection over time.
AIM, Activation-induced marker; COVID-19; COVID-19, Coronavirus disease 2019; DMSO, Dimethyl sulfoxide; ELISPOT, Enzyme-linked immunospot; OR, Odds ratio; SARS-CoV-2; SARS-CoV-2, Severe acute respiratory syndrome coronavirus-2; SFU, Spot-forming unit; T lymphocyte; VOC, Variant of concern; adaptive immunity
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
J Allergy Clin Immunol Glob
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Brasil